Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease

Clinical Neuropharmacology

Volumn 20, Issue 5, 1997, Pages 455-465

  Del Dotto, P ^d   Colzi, A ^e   Musatti, E ^a   Strolin Benedetti, M ^a   Persiani, S ^a   Fariello, R ^b   Bonuccelli, Ubaldo ^c  

^a PFIZER INC   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF PISA   (Italy)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e NONE

Author keywords

Cabergoline; L dopa; Motor fluctuations; Parkinson's disease; Pharmacokinetics

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DOSE RESPONSE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MIXTURE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; MOTOR PERFORMANCE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0030866137     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199710000-00011     Document Type: Article

References (30)

1. Fahn S. Fluctuations of disability in Parkinson's disease: pathophysiology. In: Marsden CD, Fahn S, eds. Movement Disorders. London: Butterworths; 1982:119-26.
2. Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 1994;17(suppl):32-44.
3. Obeso JA, Grandas F, Vaamonde J, Luquin MR, Martinez-Lage JM. Apomorphine infusion for motor fluctuations in Parkinson's disease. Lancet 1987;1:1376-7.
4. Vaamonde J, Luquin MR, Obeso JA. Subcutaneous lisuride infusion in Parkinson's disease. Brain 1991;114:601-14.
5. Obeso JA, Grandas F, Herreno MT, Horowski R. The role of the pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 1994;6:889-97.
6. Chase TN, Verhagen Metman L, Bravi D, Roberts JW, Sibley DR, Mouradian MM. Dopamine-receptor subtype-selective agonists in the treatment of Parkinson's disease. Clin Neuropharmacol 1995;18(suppl): 207-15.
7. Jori MC, Franceschi M, Giusti MC, et al. Clinical experience with cabergoline, a new ergoline derivative, in treatment of Parkinson's disease. In: Striefler MB, Korczyn AD, Melamed E, Youdin MBH, eds. Parkinson's Disease: Anatomy, Pathology, and Therapy, Advances in Neurology, Vol. 53. New York: Raven; 1990:539-43.
8. Lera G, Vaamonde J, Rodriguez M, Obeso JA. Cabergoline in Parkinson's disease. Ann Neurol 1990;28: 593-4.
9. Hutton TJ, Jerry LM, Brewer MA. Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology 1993;43:613-6.
10. Liberman A, Imke S, Muenter M, et al. Multicenter study of cabergoline, a long-acting dopamine receptor agonist in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology 1993;43:1981-4.
11. Rabey JM, Nissipeanu P, Inzelberg R, Korczyn AD. Beneficial effect of cabergoline, new long-lasting D2 agonist in the treatment of Parkinson's disease. Clin Neuropharmacol 1994;17:286-93.
12. Inzelberg R, Nissipeanu P, Rabey JM, Korczyn AD. Long-term tolerability and efficacy of cabergoline, a new long-acting dopaimne agonist, in Parkinson's disease. Mov Disorders 1995;10:604-7.
13. Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996;46:1062-5.
14. Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996;47:785-8.
15. Steiger MJ, El-Debas T, Anderson T, Findley LJ, Marsden CD. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996;243:68-72.
16. Ahlskog JE, Muenter MD, Maraganore DM, et al. Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline. Arch Neurol 1994;51:1236-41.
17. Rabey JM, Schwartz M, Graff E, Harsat A, Vered Y. The influence of bromocriptine on the pharmacokinetics of L-dopa in Parkinson's disease. Clin Neuropharmacol 1991;14:514-22.
18. Sutton JP, Goetz CG, Buhrnfield C, Carvey PM. The effect of bromocriptine co-therapy on L-dopa pharmacodynamics. Mov Disorders 1990;5(suppl 1):55.
19. Bentué-Ferrer D, Allain H, Reymenn JM, Sabouraud O, Van der Driessche J. Lack of pharmacokinetic influence on L-dopa by bromocriptine. Clin Neuropharmacol 1988;15:505-8.
20. Contin E, Riva R, Martinelli P, Albani F, Baruzzi A. No effect of chronic bromocriptine therapy on L-dopa pharmacokinetics in patients with Parkinson's disease. Clin Neuropharmacol 1992;15:505-8.
21. Rabey JM, Oberman Z, Scharf M, Isakow M, Bar M, Graff E. Bromocriptine blood levels after the concomitant administration of L-dopa, amantadine and biperiden in Parkinson's disease. Acta Neurol Scand 1990;81:411-5.
22. Fahn S, Elton RL, Members ol the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Vol 2. Florham Park, NJ: MacMillan Healthcare Information; 1987:153-63.
23. United States Department of Health. Educalion and Welfare. CGI: Clinical Global Impression. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Heallh; 1976:217-22.
24. Persiani S, Pianezzola E, Broutin F, Fonte G, Strolin Benedetti M. Radioimmunoassay for the synthetic ergoline derivative in biologocal fluids. J Immunoassay 1992;13:457-76.
25. Gerlach M, Klauzner N, Pruntek H. Determination of L-dopa and 3-O-methyldopa in human plasma by extraction using C18 cartridges followed by high-performance liquid chromatographic analysis with electrochemical detection. J Chromatogr 1986;180:378-85.
26. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997;48:363-8.
27. Srolin Benedetti M, Pianezzola E, Persiani S, Grimaldi R, Obeso JA. Evaluation of the linearity of cabergoline pharmacokinetics in parkinsonian patients. 10th International Symposium on Parkinson's disease. Tokyo. 1991 Abstract Book, p 240.
28. Lera G, Vaamonde J, Rodriguez M, Obeso JA. Cabergoline in Parkinson's disease: long-term follow-up. Neurology 1993;43:2587-90.
29. Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 1996;46:1051-4.
30. Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996;19:202-12.